Rabbit Antibody Variable Domains for Soluble Single-Domain Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antibodies face challenges such as immunogenicity, cytokine-associated side-effects, and difficulties in producing soluble recombinant variable domains, particularly in reducing antibody size while maintaining antigen recognition and affinity.
Innovation Solution
The development of methods to isolate and utilize rabbit VH and VL domains, along with novel CDR loops and framework regions, to create immunospecific polypeptides with enhanced stability and affinity, using phage expression libraries and chloramphenicol acetyltransferase (CAT) selection, enabling the production of highly specific single-domain antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If antibody size is reduced to single-domain fragments, then production difficulties and solubility issues are addressed, but antigen binding affinity and stability may be compromised
Solution Approach 1:
The invention extracts and utilizes only the variable domain (VH or VL) from the complete antibody structure, removing the constant domains and other chains. This extraction enables production of soluble single-domain antibodies that retain antigen binding capability while avoiding the manufacturing and solubility problems of full-length antibodies.
Solution Approach 2:
The invention changes the structural parameters of the antibody by isolating single variable domains and engineering them with optimized framework regions and CDR loops. This parameter change maintains the essential antigen binding function while improving solubility and recombinant production characteristics.
2Measurement precision
If traditional hybridoma technology is used, then monoclonal antibodies with specific epitope recognition are produced, but immunogenicity and cytokine-associated side effects occur
Solution Approach 1:
The invention extracts only the antigen-binding variable domain from the complete antibody molecule, removing the immunogenic constant regions and Fc portions. This extracted single-domain fragment maintains epitope recognition specificity while significantly reducing immunogenicity and cytokine-associated side effects in therapeutic applications.
3Productivity
If variable domains are isolated for recombinant production, then production efficiency is improved, but the domains become scarcely soluble and difficult to produce
Solution Approach 1:
The invention changes the structural parameters of isolated variable domains by engineering optimized framework regions and proper disulfide bond formation. These parameter changes improve the solubility and stability of recombinantly produced single-domain antibodies, making them easier to manufacture while maintaining high productivity.
Data Source
AI summary
The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.